Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innova...
04 Mai 2020 - 07:32AM
- Alexis RIDEAU has recognized experience in the
development, negotiation and implementation of strategic
partnerships in the life sciences field, particularly in
microbiology applied to health and infectious
diseases.
- He also has a good track record in sector analysis,
support for innovation funding, and fundraising.
DEINOVE (Euronext Growth Paris: ALDEI), a French
biotech company that uses a disruptive approach to develop
innovative antibiotics and bio-based active ingredients for
cosmetics and nutrition, announces the appointment of Alexis
RIDEAU as CEO, effective May 1, 2020.
Prior to joining DEINOVE, Alexis RIDEAU was in
charge of developing industrial relations and coordinating the
strategic partnership team at BIOASTER (Lyon/Paris), a Technology
Research Institute in applied microbiology, which specializes in
the design and use of technology innovations in the field of
microbiology to accelerate the development of medical and
nutritional industrial solutions for animal and human health.
Alexis RIDEAU has been directly involved in the
definition and implementation of the Institute's technology and
economic strategy, as well as the valorization of its
state-of-the-art technology platforms in the industrial sectors of
microbiota, antimicrobials, vaccines and diagnostic. He initiated
and implemented structuring partnerships, technologically and
financially, with major French and international players (Takeda
Pharmaceuticals, Bio-Rad Laboratories, bioMérieux, Boehringer
Ingelheim, etc.), SMEs (Kaleido Biosciences Inc., Enterome, MaaT
Pharma, LNC Therapeutics, Biofilm Pharma, etc.) and academic
institutions (INRAE MetaGenoPolis, Institut Pasteur, CNRS,
etc.).
Previously, Alexis RIDEAU held various positions
in companies operating in the technology and healthcare fields,
including support to entrepreneurs, sector analysis and fundraising
(Library House Ltd, Bionest Partners and Glaizer Group) and
directly in the field, in the conquest of new industrial markets
(MorphoSys AG, Bio-Rad Laboratories).
Alexis RIDEAU holds a PhD in Molecular and
Cellular Biology (University of Cambridge, England), a European
Magistère in Genetics and an MSc in Cellular and Molecular Genetics
(Paris Diderot University and Sorbonne University), as well as an
MBA in International Management (ESCP Europe).
"The entire DEINOVE team is very pleased to
welcome Alexis RIDEAU. His scientific expertise and extensive
experience in technology transfer and strategic partnerships are
assets that will enable DEINOVE to promote its scientific
capabilities to the Company's current and future partners. The
entire Board of Directors and I are committed to working alongside
Alexis to ensure that he takes up his new position in the best
possible way," said Charles WOLER, Chairman and Interim-CEO of
DEINOVE.
"I am impressed by the potential of the DEINOVE
teams and platforms and excited by the multitude of projects within
which the Company can enroll with high added value," adds Alexis
RIDEAU. "I will put my energy, my international experience and
my industrial and academic networks at the service of DEINOVE's
global ambitions and strive to confirm its scientific and
technological leadership."
- DEINOVE_PR_A.RIDEAU_CEO_final